Lineage Cell Therapeutics, Inc. (LCTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lineage Cell Therapeutics, Inc. (LCTX) trades at $1.28 with AI Score 39/100 (Grade D). Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for degenerative diseases. Market cap: $320.35M, Sector: Healthcare.
Last analyzed: May 10, 2026LCTX stock analysis for 2026: Analysts have set a consensus price target of $4.50 for Lineage Cell Therapeutics, Inc., suggesting 250.2% upside from the current price of $1.28. The AI MoonshotScore is 39/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
LCTX: 1/1 perspectives are bearish.
Lineage Cell Therapeutics, Inc. (LCTX) Healthcare & Pipeline Overview
Lineage Cell Therapeutics, Inc. pioneers cell therapies for degenerative diseases, including OpRegen for dry age-related macular degeneration and OPC1 for spinal cord injuries. With a focus on unmet medical needs and a gross margin of 94.2%, Lineage operates in the competitive biotechnology sector, striving to advance novel treatments.
What Is the Investment Thesis for LCTX?
Lineage Cell Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on cell therapies for degenerative diseases addresses significant unmet medical needs. Key value drivers include the successful advancement of OpRegen through clinical trials, potentially capturing a substantial share of the AMD market. Positive data from the ongoing Phase I/IIa trials for OPC1 in spinal cord injuries and VAC2 in lung cancer could also drive significant stock appreciation. The company's high gross margin of 94.2% indicates strong potential profitability upon commercialization. However, the company's negative profit margin of -436.5% underscores the substantial R&D expenses and the risks inherent in clinical-stage drug development. Successful navigation of regulatory hurdles and securing additional funding will be critical for Lineage's long-term success.
Based on FMP financials and quantitative analysis
LCTX Key Highlights
- Market Cap of $0.42B reflects investor valuation of Lineage's pipeline and technology.
- Gross Margin of 94.2% indicates strong potential profitability upon commercialization of its cell therapies.
- Profit Margin of -436.5% highlights the significant R&D investment and clinical trial expenses typical of clinical-stage biotech companies.
- Beta of 1.80 suggests higher volatility compared to the overall market, reflecting the speculative nature of biotechnology stocks.
- No Dividend Yield reflects the company's focus on reinvesting earnings into research and development.
Who Are LCTX's Competitors?
LCTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.67M | 67 |
| CRSP CRISPR Therapeutics AG | $50.52 | +0.57% | $4.87B | 44 |
| EDIT Editas Medicine, Inc. | $2.48 | +1.64% | $242.79M | 64 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
| TLX Telix Pharmaceuticals Limited | $9.56 | +1.16% | 4B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LCTX's Key Strengths?
- Proprietary cell therapy technology platform.
- Diverse pipeline of product candidates.
- Experienced management team.
- High gross margin (94.2%).
What Are LCTX's Weaknesses?
- Clinical-stage company with no currently approved products.
- High R&D expenses and negative profit margin (-436.5%).
- Reliance on successful clinical trial outcomes.
- Limited financial resources.
What Could Drive LCTX Stock Higher?
- Announcement of Phase 2 clinical trial results for OpRegen in dry AMD (expected 2027-2028).
- Initiation of Phase 2 clinical trial for OPC1 in acute spinal cord injuries (expected 2026).
- Release of Phase 1 clinical trial data for VAC2 in non-small cell lung cancer (expected late 2026).
- Continued progress in clinical development of OpRegen, OPC1, and VAC2.
- Potential for new partnerships and collaborations.
What Are the Key Risks for LCTX?
- Clinical trial failures for OpRegen, OPC1, or VAC2.
- Regulatory delays or rejection of product candidates.
- Competition from other biotechnology companies developing similar therapies.
- High cash burn rate and need for additional funding.
- Intellectual property disputes.
What Are the Growth Opportunities for LCTX?
- OpRegen for Dry Age-Related Macular Degeneration: The market for AMD treatments is substantial, driven by an aging population. If OpRegen demonstrates efficacy in Phase 2/3 trials, it could capture a significant share of this market. The global AMD market is projected to reach $12.7 billion by 2028. Lineage's competitive advantage lies in its cell therapy approach, which aims to restore lost function rather than just slow disease progression. Timeline: Phase 2/3 trial results expected in 2027-2028.
- OPC1 for Spinal Cord Injuries: The market for spinal cord injury treatments is underserved, with limited effective therapies available. Positive results from the ongoing Phase I/IIa trial could pave the way for a breakthrough treatment. The global spinal cord injury market is projected to reach $3.2 billion by 2027. Lineage's OPC1 therapy has the potential to improve neurological function and quality of life for patients with acute spinal cord injuries. Timeline: Phase 2 trial initiation expected in 2026.
- VAC2 for Non-Small Cell Lung Cancer: Lung cancer remains a leading cause of cancer-related deaths, creating a significant need for new and effective therapies. Lineage's VAC2 immunotherapy targets antigen-presenting dendritic cells to stimulate an immune response against cancer cells. The global non-small cell lung cancer market is projected to reach $38.5 billion by 2028. Early clinical trial data will be crucial in determining the potential of VAC2. Timeline: Phase 1 trial data expected in late 2026.
- Renevia for Facial Aesthetics: While not a primary focus, Renevia provides a source of revenue and demonstrates Lineage's capabilities in cell-based products. The global facial aesthetics market is growing, driven by increasing demand for non-invasive cosmetic procedures. The global facial aesthetics market is projected to reach $15.9 billion by 2027. Lineage can leverage its expertise in cell therapy to develop and market innovative aesthetic products. Timeline: Ongoing commercialization.
- Partnerships and Collaborations: Lineage's collaboration with Orbit Biomedical, Ltd. demonstrates its commitment to strategic partnerships. Collaborations can provide access to new technologies, funding, and expertise, accelerating the development and commercialization of its cell therapies. Seeking additional partnerships with pharmaceutical companies and research institutions will be crucial for Lineage's long-term growth. Timeline: Ongoing.
What Opportunities Does LCTX Have?
- Growing market for cell therapies.
- Potential for breakthrough treatments for degenerative diseases.
- Strategic partnerships and collaborations.
- Expansion into new therapeutic areas.
What Threats Does LCTX Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other biotechnology companies.
- Patent disputes.
- Difficulty in securing funding.
What Are LCTX's Competitive Advantages?
- Proprietary cell therapy technology.
- Patent protection for its product candidates.
- Clinical trial data demonstrating efficacy and safety.
- Strategic partnerships and collaborations.
- Expertise in cell-based product development and manufacturing.
What Does LCTX Do?
Lineage Cell Therapeutics, Inc., founded in 1990 and headquartered in Carlsbad, California, is a clinical-stage biotechnology company dedicated to developing innovative cell therapies for degenerative diseases. Originally incorporated as BioTime, Inc., the company rebranded in August 2019 to reflect its focus on cell-based therapeutics. Lineage's primary focus is on addressing unmet medical needs in areas such as retinal, neurological, and oncological disorders. Their lead product candidate, OpRegen, is a retinal pigment epithelium (RPE) cell replacement therapy currently in Phase I/IIa clinical trials for the treatment of dry age-related macular degeneration (AMD), a significant cause of vision loss in the elderly. Another key program, OPC1, is an oligodendrocyte progenitor cell therapy in Phase I/IIa trials for acute spinal cord injuries. Additionally, Lineage is developing VAC2, an allogeneic cancer immunotherapy using antigen-presenting dendritic cells, in a Phase I trial for non-small cell lung cancer. The company also markets Renevia, a facial aesthetics product. Lineage collaborates with Orbit Biomedical, Ltd. to advance its therapeutic programs. With a team of 70 employees, Lineage is committed to advancing its pipeline of cell therapies and improving patient outcomes.
What Products and Services Does LCTX Offer?
- Develop cell therapies for degenerative diseases.
- Focus on retinal, neurological, and oncological disorders.
- Develop OpRegen for dry age-related macular degeneration.
- Develop OPC1 for acute spinal cord injuries.
- Develop VAC2 for non-small cell lung cancer.
- Offer Renevia, a facial aesthetics product.
- Engage in research and development of therapeutic products.
How Does LCTX Make Money?
- Develop and commercialize cell therapies.
- Generate revenue through product sales (e.g., Renevia).
- Out-license or partner for further development and commercialization of therapies.
- Secure funding through venture capital and public offerings.
What Industry Does LCTX Operate In?
Lineage Cell Therapeutics operates within the rapidly evolving biotechnology industry, which is characterized by intense competition, high R&D costs, and stringent regulatory oversight. The market for cell therapies is projected to grow significantly, driven by an aging population and increasing prevalence of degenerative diseases. Lineage's focus on retinal, neurological, and oncological disorders positions it within key growth areas. Competitors include larger pharmaceutical companies and specialized biotech firms also developing cell-based therapies. Success in this landscape requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships.
Who Are LCTX's Key Customers?
- Patients with degenerative diseases (e.g., AMD, spinal cord injuries, lung cancer).
- Physicians and healthcare providers.
- Hospitals and clinics.
- Aesthetic practices (for Renevia).
LCTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- LCTX insiders seem to be holding steady, suggesting they believe in the company's long-term prospects. Confidence level: 75%.
- There's a growing buzz in the community about potential partnerships, like when smaller biotechs partnered with big pharma for drug development in the past.
- The general sentiment seems to be that LCTX is undervalued, a classic 'sleeper stock' scenario.
- The market's perception of regenerative medicine is improving, which could benefit LCTX.
Bear Case
- Community chatter reveals concerns about LCTX's ability to scale up production if demand increases.
- Some investors are worried about potential regulatory hurdles, similar to what other biotech companies have faced.
- A few influential voices in the community are skeptical about the long-term efficacy of LCTX's technology.
- There's a lingering doubt about whether LCTX can maintain its competitive edge against larger players in the market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
LCTX Latest News
-
Earnings Scheduled For May 12, 2026
benzinga · May 12, 2026
-
Lineage Announces Formation of Scientific Advisory Board
businesswire.com · Apr 13, 2026
-
Earnings Scheduled For March 5, 2026
benzinga · Mar 5, 2026
-
Earnings Scheduled For November 6, 2025
benzinga · Nov 6, 2025
LCTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LCTX.
Price Targets
Consensus target: $4.50
LCTX MoonshotScore
What does this score mean?
The MoonshotScore rates LCTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Brian Culley
CEO
Brian Culley serves as the CEO of Lineage Cell Therapeutics, bringing extensive experience in the biopharmaceutical industry. His background includes leadership roles in various biotech companies, focusing on strategic development, clinical operations, and commercialization. He has a proven track record in guiding companies through critical stages of growth and development, including clinical trials and regulatory submissions. His expertise spans multiple therapeutic areas, including regenerative medicine and oncology. Culley's leadership is instrumental in driving Lineage's strategic vision and advancing its pipeline of cell therapies.
Track Record: Since joining Lineage, Brian Culley has focused on advancing the company's clinical programs, particularly OpRegen and OPC1. Key achievements include securing funding for clinical trials, strengthening strategic partnerships, and navigating regulatory milestones. Under his leadership, Lineage has made significant progress in its clinical development programs, positioning the company for potential future commercial success.
What Investors Ask About Lineage Cell Therapeutics, Inc. (LCTX) — Healthcare
What does Lineage Cell Therapeutics, Inc. do?
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel cell therapies for the treatment of degenerative diseases. Their primary focus is on addressing unmet medical needs in areas such as retinal, neurological, and oncological disorders. The company's lead product candidates include OpRegen for dry age-related macular degeneration, OPC1 for acute spinal cord injuries, and VAC2 for non-small cell lung cancer. Lineage aims to restore lost function and improve patient outcomes through its innovative cell-based therapies.
What do analysts say about LCTX stock?
Analyst coverage of Lineage Cell Therapeutics (LCTX) is limited, reflecting its status as a clinical-stage biotechnology company. Current valuations are primarily based on the potential of its pipeline, particularly OpRegen. Key metrics to watch include clinical trial progress, regulatory milestones, and cash runway. Given the inherent risks in biotechnology, analyst opinions are subject to change based on clinical data and market conditions. Investors should conduct their own due diligence and consider their risk tolerance before investing.
What are the main risks for LCTX?
Lineage Cell Therapeutics faces several key risks inherent to its business model. Clinical trial failures represent a significant risk, as the success of its product candidates depends on demonstrating efficacy and safety. Regulatory hurdles and delays could also impact timelines and increase costs. Competition from other biotechnology companies developing similar therapies poses a threat to market share. Furthermore, Lineage's high cash burn rate necessitates ongoing fundraising, which could dilute existing shareholders. Intellectual property disputes also represent a potential risk.
What are the key factors to evaluate for LCTX?
Lineage Cell Therapeutics, Inc. (LCTX) holds an AI score of 39/100 (low). Analysts target $4.50 (+250%). Not financial advice.
How frequently does LCTX data refresh on this page?
LCTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LCTX's recent stock price performance?
Lineage Cell Therapeutics, Inc. (LCTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary cell therapy technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LCTX overvalued or undervalued right now?
Valuing Lineage Cell Therapeutics, Inc. (LCTX) requires multiple metrics. Analysts target $4.50 (+250%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LCTX?
Before investing in Lineage Cell Therapeutics, Inc. (LCTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment decisions should be based on individual risk tolerance and due diligence.